These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38192593)

  • 21. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
    Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
    J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.
    Morton JI; Marquina C; Shaw JE; Liew D; Polkinghorne KR; Ademi Z; Magliano DJ
    Diabetologia; 2023 Apr; 66(4):642-656. PubMed ID: 36404375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
    Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
    PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
    Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
    Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
    Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z
    Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.
    Zhang L; Bao Y; Riaz M; Tiller J; Liew D; Zhuang X; Amor DJ; Huq A; Petelin L; Nelson M; James PA; Winship I; McNeil JJ; Lacaze P
    Genet Med; 2019 Sep; 21(9):1958-1968. PubMed ID: 30773532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Jaine R; Kvizhinadze G; Nair N; Blakely T
    Lung Cancer; 2020 Jun; 144():99-106. PubMed ID: 32317183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
    Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
    JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 37. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Jaine R; Kvizhinadze G; Nair N; Blakely T
    Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price.
    Kim H; Goodall S; Liew D
    J Med Econ; 2021; 24(1):893-899. PubMed ID: 34259119
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States.
    Guzauskas GF; Jiang S; Garbett S; Zhou Z; Spencer SJ; Snyder SR; Graves JA; Williams MS; Hao J; Peterson JF; Veenstra DL
    Genet Med; 2022 May; 24(5):1017-1026. PubMed ID: 35227606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.